Search Results - "Ballas, M. S."

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC) by Camidge, D. R., Ballas, M. S., Dubey, S., Haigentz, M., Rosen, P. J., Spicer, J. F., West, H. J., Shah, G. D., Youssoufian, H., Mita, A. C.

“…Abstract only…”
Get full text

A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC by Blumenthal, G. M., Ballas, M. S., Bernstein, W., Shamloo, B. K., Root, H., Helsabeck, C., Chun, G., Figg, W. D., Giaccone, G., Dennis, P. A.

“…Abstract only…”
Get full text

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma by Callander, Natalie S., Ribrag, Vincent, Richardson, Paul G., Nooka, Ajay K., Song, Kevin, Uttervall, Katarina, Minnema, Monique C., Weisel, Katja, Quach, Hang, Min, Chang-Ki, Ballas, Marc S., Li, Xiaofang, Ratia, Nirav, Kaisermann, Morrys, Holkova, Beata, Trudel, Suzanne

“…Introduction: Single-agent belantamab mafodotin (belamaf), a B-cell maturation antigen-targeting antibody-drug conjugate, achieved durable responses with a…”
Get full text

Prognostic significance of clinical features and Akt activation in the survival of patients with bronchioloalveolar carcinoma (BAC) by Ballas, M. S., Tsurutani, J., Steinberg, S., Robertson, M., Egilsson, V., Dennis, P. A.

“…Abstract only 7217 Background: Lung cancer is the leading cause of cancer related mortality in the world. BAC is a subset of NSCLC that has recently gained…”
Get full text

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC by Ballas, Marc S, Chachoua, Abraham

“…Lung cancer remains a leading cause of death globally, with the most frequent type, nonsmall cell lung cancer (NSCLC), having a 5-year survival rate of less…”
Get full text

Rapid Desensitization Did Not Prevent Febrile “Idiosyncratic” Reactions to Oxaliplatin by Mathew, A, Ballas, M.S, Gorsky, M, Feigenbaum, B.A

“…The literature contains reports of 4 patients who developed reactions during, or up to 24 hours after oxaliplatin infusion, with fever being a predominant…”
Get full text

Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma by Tsurutani, Junji, Ballas, Marc S, Dennis, Phillip A

Get full text

A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer by Ballas, Marc S., Dennis, Phillip A.

“…Commentary to: Evaluation of Irinotecan plus Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer John R. Murren, Nicolaj Andersen, Deborah Brandt,…”
Get full text